Biotech entity
Every one of those 2 sits in a single category, clinical-trial. Retraction Watch is most often covered alongside Nature, which appears in 2 of these 2 stories. Across a 7-day span, the pace is roughly 2 stories per week. The 8 average consequence score is above the beat benchmark of 5.9 in the same window.
Last mentioned: Aug 1, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, clinical-trial. Retraction Watch is most often covered alongside Nature, which appears in 2 of these 2 stories. Across a 7-day span, the pace is roughly 2 stories per week. The 8 average consequence score is above the beat benchmark of 5.9 in the same window. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline. We currently track 2 Biotech stories that mention Retraction Watch, published between July 26, 2026 and August 1, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 51 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Retraction Watch. Shared-story counts are live from our verified record — not editorial picks.
Shanghai Jiaotong University launches investigation
The university forms a working group to comprehensively investigate the clinical trial and the associated Nature paper.
Joint investigation report published
Science magazine and Retraction Watch release findings detailing the undisclosed death and ethical lapses, bringing the case to public attention.
University investigation launched
Shanghai Jiao Tong University School of Medicine announces a special working group to investigate and promises 'serious action'.
Investigative report published
Science and Retraction Watch publish a joint exposé revealing the death and lack of disclosure, triggering international scrutiny.
Mei receives gene-editing therapy
Six-year-old girl with rare cognitive delay condition receives spinal infusion of trillions of engineered viruses in an experimental trial.
Fatal gene-editing trial conducted
A young girl receives an experimental gene-editing treatment for a developmental-delay-linked genetic defect at Xinhua Hospital; she later dies, an outcome the ethics board deems treatment-related.
He Jiankui gene-edited babies scandal breaks
Chinese scientist He Jiankui announces the birth of the world’s first gene-edited babies, triggering global outrage and prompting China to tighten research regulations.
A young girl's death in an undisclosed gene-editing trial, funded by $860,000 from her parents, has triggered an investigation at Shanghai Jiaotong University. The case exposes critical ethics gaps in China's surging biopharma sector and raises alarms for investors, partners, and regulators worldwide.
Source: yahoo.com · egyptindependent.com
The death of a young patient in a Chinese gene-editing trial, hidden from a subsequent Nature publication, sends shockwaves through the biotech sector. Industry leaders must grapple with the implications for gene therapy research integrity, funding, and the race to deliver transformative neurological treatments.
Source: channelnewsasia.com · straitstimes.com
Retraction Watch is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
